Antares Pharma (NASDAQ:ATRS)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a report issued on Tuesday, Stock Ratings Network reports.
Separately, analysts at Ladenburg Thalmann raised their price target on shares of Antares Pharma from $5.00 to $5.75 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock.
Shares of Antares Pharma (NASDAQ:ATRS) opened at 4.53 on Tuesday. Antares Pharma has a 52-week low of $3.35 and a 52-week high of $4.72. The stock has a 50-day moving average of $4.30 and a 200-day moving average of $4.1. The company’s market cap is $576.0 million.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.01. The company had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.82 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 28.9% on a year-over-year basis. On average, analysts predict that Antares Pharma will post $-0.15 earnings per share for the current fiscal year.
Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.